Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 139


Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2010 Feb 15;16(4):1179-90. doi: 10.1158/1078-0432.CCR-09-1787. Epub 2010 Feb 9.


Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K.

Cancer Res. 2004 May 1;64(9):3198-208.


LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.

Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K.

PLoS Genet. 2012;8(3):e1002538. doi: 10.1371/journal.pgen.1002538. Epub 2012 Mar 29.


Targeting low molecular weight cyclin E (LMW-E) in breast cancer.

Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K.

Breast Cancer Res Treat. 2012 Apr;132(2):575-88. doi: 10.1007/s10549-011-1638-4. Epub 2011 Jun 22.


Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.

Nair BC, Vallabhaneni S, Tekmal RR, Vadlamudi RK.

Breast Cancer Res. 2011 Aug 11;13(3):R80. doi: 10.1186/bcr2929.


GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.

Abrhale T, Brodie A, Sabnis G, Macedo L, Tian C, Yue B, Serrero G.

BMC Cancer. 2011 Jun 9;11:231. doi: 10.1186/1471-2407-11-231.


AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.

O'Hara J, Vareslija D, McBryan J, Bane F, Tibbitts P, Byrne C, Conroy RM, Hao Y, Gaora PÓ, Hill AD, McIlroy M, Young LS.

Clin Cancer Res. 2012 Jun 15;18(12):3305-15. doi: 10.1158/1078-0432.CCR-11-3300. Epub 2012 May 1.


Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA.

Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2.


Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2.

Musgrove EA, Hunter LJ, Lee CS, Swarbrick A, Hui R, Sutherland RL.

J Biol Chem. 2001 Dec 14;276(50):47675-83. Epub 2001 Oct 4.


Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.

Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K.

Cancer Res. 2011 May 1;71(9):3377-86. doi: 10.1158/0008-5472.CAN-10-4086. Epub 2011 Mar 8.


Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.

Nair HB, Kirma NB, Ganapathy M, Vadlamudi RK, Tekmal RR.

Steroids. 2011 Jul;76(8):792-6. doi: 10.1016/j.steroids.2011.02.038. Epub 2011 Apr 6.


Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.

Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, Mehta RG.

J Steroid Biochem Mol Biol. 2013 Jan;133:30-42. doi: 10.1016/j.jsbmb.2012.08.004. Epub 2012 Aug 23.


The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.

Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K.

J Biol Chem. 2005 Apr 15;280(15):15148-57. Epub 2005 Feb 10.


Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.

Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH.

Breast Cancer Res. 2014 Jan 29;16(1):R15. doi: 10.1186/bcr3609.


Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.

Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K.

Cell Cycle. 2012 Apr 1;11(7):1468-76. doi: 10.4161/cc.19882. Epub 2012 Apr 1.


The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.

Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH.

Breast Cancer Res Treat. 2012 Oct;135(3):681-92. doi: 10.1007/s10549-012-2148-8. Epub 2012 Aug 10.


Low-molecular-weight cyclin E: the missing link between biology and clinical outcome.

Akli S, Keyomarsi K.

Breast Cancer Res. 2004;6(5):188-91. Epub 2004 Jul 7.


Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.

Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM.

Clin Cancer Res. 2009 May 15;15(10):3396-405. doi: 10.1158/1078-0432.CCR-08-3127.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk